Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public a quick fix and a path to losing excess weight or resolving their diabetic issues. GLP-1 drugs are revolutionizing medicine and the treatment of patients with diabetes, obesity, and other disorders associated with obesity.
With the growing demand of these drugs, pharmaceutical companies, health care providers, telemedicine companies, and pharmaceutical compounders are facing new challenges with GLP-1s. Organizations need to know how to navigate a complex set of issues, including patent considerations, regulatory issues, lawsuits, and M&A activity.
鶹ֱ’s and sectors invite you to join us for a webinar on how your organization can navigate the crossroads of GLP-1s and prepare for this evolving landscape.
This webinar will explore the following GLP-1 topics:
Please click to watch the recording.
Applications for accreditation will be submitted to CA, CO, FL, IL, NY, TX, UT, VA, and WI. Uniform Certificates of Attendance will be provided to attendees licensed in other jurisdictions so they may self-apply if their jurisdiction allows.
鶹ֱ & Lardner LLP is an approved MCLE provider in California, Colorado, Illinois, New York, Texas, and Utah.
For purposes of New York CLE credit, this program is appropriate for both newly admitted and experienced attorneys.
Certificates of attendance will be distributed to eligible participants approximately eight weeks after the program via email.
